Mediclinic International Plc : An appropriate purchase level
Entry price | Target | Stop-loss | Potential |
---|
GBX 877 |
GBX 0 |
GBX 816 |
-100% |
---|
Bright outlook and a recent sharp drop as arguments.
Financials forecast are encouraging, sales and EBITDA should keep a 2 digits growth. Moreover, the consensus is very optimistic, the average target price shows a +36% potential. In addition none analyst has a “sell” opinion. The current P/E ratio is below the industry average.
The share has been evolving in a slight downtrend for many months. Moving averages are flat and technical indicators illustrate the oversold situation. The stock is presently near its lower trend line, which was successfully tested. Furthermore, the closeness of the GBp 840 long term support militate also for a forthcoming reversal.
Consequently, investors may open a long position at current prices and target the GBp 985 mid-term resistance. A stop loss should be set below the GBp 825 daily support.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.